We are aware of today’s media reports saying that Novartis intends to halt the development of branaplam, a promising oral drug for SMA. We are unable to confirm these news at this stage. We expect to have more information in the following days.
During an election period, Government Departments are restricted in the announcements that they are able to make or the information that they are able to publish. The ongoing communication between NHS England and the Patient Advocacy Groups (PAGs) about implementation…
TreatSMA hosted its second Physio with Marion session on Sunday, and thanks to Marion and all of those who took part in asking questions, it was another great success.
Earlier this year TreatSMA met with a number of MPs, including deputy speaker of the House of Commons, to talk about the possibility of introducing a high cost medicine fund.
Progress is being made to develop a muscle-strengthening drug in SMA. Scholar Rock, Inc. has just announced interim results of a phase-2 clinical trial of their experimental drug SRK-015. SRK-015 aims to improve muscle strength in people with spinal muscular…
Over 90 days have passed since NICE published their final guidance for nusinersen meaning that treatment should now be available. TreatSMA, SMA UK and MDUK will all be representing the SMA Community as part of the Oversight Committee for the…